Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S Common Stock
(NY:
NVO
)
49.23
-0.14 (-0.28%)
Official Closing Price
Updated: 7:00 PM EST, Feb 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
11,296,430
Open
48.83
Bid (Size)
49.10 (500)
Ask (Size)
49.28 (100)
Prev. Close
49.37
Today's Range
48.63 - 49.35
52wk Range
43.08 - 93.80
Shares Outstanding
N/A
Dividend Yield
2.37%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
February 17, 2026
In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...
Via
MarketMinute
Topics
Earnings
Economy
NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection
↗
February 17, 2026
The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants.
Via
Stocktwits
Topics
Lawsuit
Performance
YTD
-6.0%
-6.0%
1 Month
-18.9%
-18.9%
3 Month
+0.5%
+0.5%
6 Month
-9.3%
-9.3%
1 Year
-40.2%
-40.2%
More News
Read More
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy?
↗
February 17, 2026
Via
The Motley Fool
Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report
↗
February 12, 2026
Via
Stocktwits
HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In?
↗
February 11, 2026
Via
Stocktwits
Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy?
↗
February 16, 2026
Via
The Motley Fool
Got $500? 2 Pharma Stocks to Buy and Hold Forever.
↗
February 14, 2026
Via
The Motley Fool
Novo Nordisk To Meet Wegovy Pill Demand In US Before Expanding To Avoid Supply Shortage, Says CEO Doustdar
↗
February 13, 2026
Via
Stocktwits
Topics
Lawsuit
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026
↗
February 13, 2026
Via
The Motley Fool
Topics
Intellectual Property
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout?
↗
February 12, 2026
Via
Stocktwits
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.
↗
February 12, 2026
Via
The Motley Fool
Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs
↗
February 12, 2026
Via
Benzinga
Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly
↗
February 11, 2026
Via
Stocktwits
Topics
Intellectual Property
The Greenland Gambit: Inside the Transatlantic Tariff Shock and the Future of Arctic Sovereignty
February 11, 2026
Via
MarketMinute
Topics
Bonds
Economy
Government
Disney Has Its Next CEO
↗
February 11, 2026
Via
The Motley Fool
Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.
↗
February 11, 2026
Via
The Motley Fool
Biotech Beat Nvidia in 2025. Can It Do It Again?
↗
February 11, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore
↗
February 11, 2026
Via
The Motley Fool
Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know
↗
February 10, 2026
Via
The Motley Fool
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
February 10, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Earnings
Economy
Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial
↗
February 10, 2026
Via
Stocktwits
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?
↗
February 10, 2026
Via
The Motley Fool
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit
↗
February 09, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Lawsuit
Stocks
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
↗
February 09, 2026
Via
The Motley Fool
Topics
Intellectual Property
Lawsuit
Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment?
↗
February 09, 2026
Via
The Motley Fool
Topics
Intellectual Property
Frequently Asked Questions
Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 49.23
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 02/18/26 07:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.